annb0t
Top 20
Mesoblast Limited
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022.
Financial Highlights
Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter increased 36% to US$1.9 millio...
>>> Read more: Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022.
Financial Highlights
Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter increased 36% to US$1.9 millio...
>>> Read more: Appendix 4C Quarterly Activity Report
